Regencell Bioscience (NASDAQ:RGC) Stock Price Down 15.1% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 15.1% during trading on Wednesday . The company traded as low as $10.17 and last traded at $9.41. Approximately 83,300 shares were traded during mid-day trading, a decline of 70% from the average session volume of 279,030 shares. The stock had previously closed at $11.08.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Regencell Bioscience Stock Down 14.2%

The business has a fifty day simple moving average of $24.53 and a 200 day simple moving average of $25.79.

Regencell Bioscience (NASDAQ:RGC) last posted its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the second quarter worth approximately $1,701,000. BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $768,000. Vident Advisory LLC boosted its stake in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the period. XTX Topco Ltd acquired a new stake in Regencell Bioscience during the third quarter worth approximately $598,000. Finally, Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience during the fourth quarter worth approximately $275,000. Institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.